Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Apr 15, 2015
Sangamo BioSciences Announces First Quarter 2015 Conference Call and Webcast

Mar 18, 2015
Sangamo BioSciences Announces Participation In The 3rd Annual Regen Med Investor Day Meeting In New York


View all »Events & Presentations

Apr 22, 2015 at 5:00 PM ET
Sangamo's Quarterly Teleconference

Jun 22, 2015 at 9:00 AM PT
2015 Annual Meeting of Stockholders

Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
14.50
Change:
- 1.02
Day High:
15.42
Day Low:
14.24
Volume:
1,007,600
4:00 PM ET on Apr 17, 2015

Shareholder Tools